Dual Raltegravir–Darunavir/Ritonavir Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy Including a Ritonavir-Boosted Protease Inhibitor Plus Two Nucleoside/Nucleotide Reverse Transcriptase Inhibitors-Reference-Cited by-同舟云学术

Dual Raltegravir–Darunavir/Ritonavir Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy Including a Ritonavir-Boosted Protease Inhibitor Plus Two Nucleoside/Nucleotide Reverse Transcriptase Inhibitors

Published:2016-01-02 Issue:1 Volume:17 Page:38-47
ISSN:1528-4336
Container-title:HIV Clinical Trials
language:en
Short-container-title:HIV Clinical Trials

Author:

Calza Leonardo,Danese Ilaria,Magistrelli Eleonora,Colangeli Vincenzo,Manfredi Roberto,Bon Isabella,Re Maria Carla,Conti Matteo,Viale Pierluigi

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Infectious Diseases

Link

http://www.tandfonline.com/doi/pdf/10.1080/15284336.2015.1122874

Reference30 articles.

1. Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services (DHHS) (last update November 13, 2014). Available at: http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf

2. European AIDS Clinical Society (EACS) guidelines. Version 7.1 (November 2014). Available at: http://www.eacsociety.org/Portals/0/GUIDELINES/English%20PDF%20-%20Version%207.1.pdf

3. Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection

4. Mortality in the Highly Active Antiretroviral Therapy Era

5. Renal disease in HIV-infected individuals

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nucleos(t)ide reverse transcriptase inhibitor-sparing regimens in the era of standard 3-drug combination therapies for HIV-1 infection;Global Health & Medicine;2020-12-31

2. HPLC-MS/MS method for the simultaneous quantification of dolutegravir, elvitegravir, rilpivirine, darunavir, ritonavir, raltegravir and raltegravir-β-d-glucuronide in human plasma;Journal of Pharmaceutical and Biomedical Analysis;2020-04

3. Maintenance of virologic suppression and improvement in comorbidities after simplification to raltegravir plus boosted darunavir among treatment-experienced HIV-infected patients;International Journal of STD & AIDS;2020-03-05

4. Two‐drug antiretroviral regimens: an assessment of virologic response and durability among treatment‐experienced persons living with HIV in the OPERA ® Observational Database;Journal of the International AIDS Society;2019-12

5. Lack of impact of protease inhibitor resistance-associated mutations on the outcome of HIV-1-infected patients switching to darunavir-based dual therapy;Infectious Diseases;2019-11-25